💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ondansetron

CHEMBL46 Phase 4 Aprovado Small molecule
Half-Life
3-5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
293.4 g/mol
LogP
2.3
Phase
4

A serotonin receptor antagonist preventing chemotherapy-induced and post-operative nausea and vomiting.

Peso Molecular

293,3660 g/mol

LogP

2,30

TPSA

39,80 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Melanoma Oncology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Obesity Lymphoma Major Depressive Disorder Breast Cancer Chronic Pain HIV/AIDS Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Classes de Medicamentos

A — A - Alimentary Tract and Metabolism

Mecanismo de Ação

Selective 5-HT3 receptor antagonist.

Pharmacokinetics (PK)

Half-Life 3-5 hours

Pharmacodynamics (PD)

Mecanismo

Selective 5-HT3 receptor antagonist.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O

                

                

                
                

                    
InChI

                    
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H19N3O

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
Ligações Rotacionáveis

                        
2

                    

                    
                    
                    

                        
Átomos Pesados

                        
22

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            SLC6A4 (Serotonin Transporter)
                            Other
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            HRH1 (Histamine H1 Receptor)
                            Antagonist
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Escitalopram
                            
                        

                        
                        
Escitalopram and ondansetron together carry dual risks: serotonin syndrome and additive QT interval prolongation, making this combination particularly dangerous.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Azithromycin
                            
                        

                        
                        
Azithromycin and ondansetron both prolong the cardiac QT interval; their combination substantially increases the risk of torsades de pointes.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits the metabolism of ondansetron and both drugs prolong the QT interval, creating a compounded arrhythmia risk.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Ciprofloxacin
                            
                        

                        
                        
Ciprofloxacin and ondansetron both prolong the QT interval; combined use raises the risk of torsades de pointes and sudden cardiac death.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Hydroxychloroquine
                            
                        

                        
                        
Hydroxychloroquine and ondansetron both prolong cardiac repolarization via hERG blockade; concurrent use substantially elevates arrhythmia risk.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
A serotonin receptor antagonist preventing chemotherapy-induced and post-operative nausea and vomiting.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective 5-HT3 receptor antagonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Ondansetron: Half-life: 3-5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Ondansetron is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL46.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4595.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.